Veterinary Assistive Reproduction Technology Market Size, Share, Report 2024-2033
The global veterinary assistive reproduction technology market size was estimated at around USD 2.84 billion in 2023 and it is projected to hit around USD 5.84 billion by 2033, growing at a CAGR of 7.48% from 2023 to 2033.
The veterinary assisted reproduction technology (ART) market has witnessed significant growth in recent years, reflecting the increasing demand for advanced reproductive solutions in animal healthcare. As advancements in technology continue to redefine veterinary practices, ART emerges as a pivotal aspect, addressing challenges and enhancing breeding outcomes across various animal species.
The growth of the veterinary assisted reproduction technology (ART) market can be attributed to several key factors. Firstly, continual technological advancements in artificial insemination, embryo transfer, and in vitro fertilization have significantly improved breeding outcomes, fostering increased adoption across various animal species. Secondly, a heightened awareness among pet owners, livestock breeders, and animal enthusiasts regarding the benefits of assisted reproduction technologies has driven market expansion. The economic significance of these technologies, particularly in the agricultural sector, where improved breeding methods enhance livestock productivity and yield, further fuels market growth. Additionally, the segmentation of the market based on technology, animal type, and end user allows for targeted solutions, catering to specific needs within the veterinary landscape. As the industry continues to address regulatory challenges and invest in research and development, it is well-positioned for sustained growth, with ongoing innovations presenting new opportunities for market players.
| Report Coverage | Details |
| Market Revenue by 2033 | USD 5.84 billion |
| Growth Rate from 2024 to 2033 | CAGR of 7.48% |
| Revenue Share of North America in 2023 | 32% |
| Base Year | 2023 |
| Forecast Period | 2024 to 2033 |
| Market Analysis (Terms Used) | Value (US$ Million/Billion) or (Volume/Units) |
The bovine segment held the largest revenue share in 2023 within the animal type category. This dominance is attributed to a growing demand for dairy and beef products, advancements in bovine reproduction technologies, the imperative for sustainable food production, and supportive initiatives implemented by both government organizations and industry stakeholders. For example, Genus Plc witnessed notable sales of approximately USD 338 million from its bovine division, Genus ABS, in 2022. This figure escalated to USD 396 million in 2022, underscoring the evident demand and adoption of the company's bovine genetic solutions.
Conversely, the other animals segment predicted to grow at the remarkable CAGR from 2024 to 2033. This anticipated growth is driven by an upsurge in the demand for artificial insemination (AI) among dog breeders and owners, along with the global exchange of semen from companion animals. Breeders, particularly those focusing on dogs, frequently aim to produce animals with specific traits, including temperament, appearance, and health characteristics. Assisted reproduction technologies play a pivotal role in facilitating more controlled and precise breeding practices, empowering breeders to selectively propagate desirable traits. Moreover, the increasing efficacy of assistive reproduction techniques serves as a compelling factor, motivating breeders to adopt these technologies with the confidence of achieving successful pregnancies and ensuring the health of offspring.
In 2022, the normal semen segment dominated the market share, while the sexed semen segment is anticipated to exhibit the highest Compound Annual Growth Rate (CAGR) from 2024 to 2033. The prevalence of normal sperm over sexed sperm is primarily driven by its lower cost and superior fertility rates. Achieving excellent results through the use of frozen sperm, maintaining high-quality genetic merit bulls at sperm stations, and providing AI sperm dosages of utmost quality contribute to the substantial market share of the normal semen segment.
In contrast, sexed semen offers a more precise control over the gender of offspring, allowing farmers to strategically focus on economically valuable traits. This distinction is particularly advantageous in dairy farming, where female calves hold greater value than males due to their potential as future milk-producing cows. The utilization of sexed semen in dairy farming aids in increasing the number of female calves, thereby enhancing the overall efficiency and profitability of dairy operations.
The artificial insemination segment generated the maximum market share of 91% in 2023. Meanwhile, the In Vitro Fertilization (IVF) segment is anticipated to experience the most rapid Compound Annual Growth Rate (CAGR) from 2024 to 2033. Artificial insemination, a well-established method, has been a mainstay in both the companion and livestock sectors for decades. Conversely, Embryo Transfer (ET) and IVF are relatively recent introductions into the veterinary domain. For instance, in March 2018, the National Dairy Development Board inaugurated an Ovum Pick-up and In Vitro Embryo Production (OPU-IVEP) facility in India, aimed at research and training initiatives. The facility's objective was to make this technology more accessible and affordable for dairy farmers in India.
Globally, artificial insemination is widely adopted. However, ET and IVF represent niche and emerging technologies, exhibiting limited adoption as of 2022. A study published by Elsevier, Inc. and Fass, Inc. in December 2022 reported an increasing trend in the use of assisted reproduction technologies, particularly IVF, in dairy cattle. The study, analyzing a phenotypic database comprising approximately 0.32 million Holstein animals in Québec, Canada, between 2012 and 2019, revealed that during this period, around 0.30 million cows were conceived through artificial insemination, 12,993 via multiple ovulation embryo transfer (MOET), and 732 through IVF. This data underscores the evolving landscape and growing acceptance of advanced reproductive technologies in the veterinary sector.
North America held the largest revenue share of 32% in 2023. This is owing to the presence of key industry players including, URUS Group LP, Semex, Select Sires Inc., Swine Genetics International, and STgenetics; wide-scale adoption of veterinary reproductive techniques; increasing demand for sustainable animal protein; and growing need for reproduction technology to improve animal breeding. Asia Pacific is anticipated to grow at the highest CAGR from 2024 to 2033 due to rising awareness about assistive reproduction technologies, high livestock population, and supportive government initiatives.As per FAO and internal GVR estimates, the global cattle and pig population in 2022 was estimated to be 1.5 billion and 930 million, respectively; out of this, an estimated 475 million cattle and 506 million pigs were in Asia Pacific alone.
Thus, a high population of livestock is expected to propel the demand for artificial insemination, ET, and IVF techniques to improve breeding outcomes. The demand for veterinary assistive reproduction technologies is also expected to increase in Latin America and Middle East & Africa as these regions have the highest population of leading livestock animals (e.g., cattle, pigs, goats) after Asia Pacific and currently low penetration of advanced reproduction techniques in animal husbandry. industry players have thus begun to focus their strategies on improving their presence in these emerging regions. For instance, Semen Cardona S.L. is exploring opportunities in Mexico, Colombia, etc., to expand their business. The company distributed more than 0.7 million doses of semen in Mexico in 2022. Similar initiatives are expected to drive market growth in the coming years.
By Animal Type
By Product
By Conception Method
By Region
Chapter 1. Introduction
1.1. Research Objective
1.2. Scope of the Study
1.3. Definition
Chapter 2. Research Methodology
2.1. Research Approach
2.2. Data Sources
2.3. Assumptions & Limitations
Chapter 3. Executive Summary
3.1. Market Snapshot
Chapter 4. Market Variables and Scope
4.1. Introduction
4.2. Market Classification and Scope
4.3. Industry Value Chain Analysis
4.3.1. Raw Material Procurement Analysis
4.3.2. Sales and Distribution Animal Type Analysis
4.3.3. Downstream Buyer Analysis
Chapter 5. COVID 19 Impact on Veterinary Assistive Reproduction Technology Market
5.1. COVID-19 Landscape: Veterinary Assistive Reproduction Technology Industry Impact
5.2. COVID 19 - Impact Assessment for the Industry
5.3. COVID 19 Impact: Global Major Government Policy
5.4. Market Trends and Opportunities in the COVID-19 Landscape
Chapter 6. Market Dynamics Analysis and Trends
6.1. Market Dynamics
6.1.1. Market Drivers
6.1.2. Market Restraints
6.1.3. Market Opportunities
6.2. Porter’s Five Forces Analysis
6.2.1. Bargaining power of suppliers
6.2.2. Bargaining power of buyers
6.2.3. Threat of substitute
6.2.4. Threat of new entrants
6.2.5. Degree of competition
Chapter 7. Competitive Landscape
7.1.1. Company Market Share/Positioning Analysis
7.1.2. Key Strategies Adopted by Players
7.1.3. Vendor Landscape
7.1.3.1. List of Suppliers
7.1.3.2. List of Buyers
Chapter 8. Global Veterinary Assistive Reproduction Technology Market, By Animal Type
8.1. Veterinary Assistive Reproduction Technology Market, by Animal Type, 2024-2033
8.1.1 Bovine
8.1.1.1. Market Revenue and Forecast (2021-2033)
8.1.2. Swine
8.1.2.1. Market Revenue and Forecast (2021-2033)
8.1.3. Ovine
8.1.3.1. Market Revenue and Forecast (2021-2033)
8.1.4. Caprine
8.1.4.1. Market Revenue and Forecast (2021-2033)
8.1.5. Equine
8.1.5.1. Market Revenue and Forecast (2021-2033)
8.1.6. Other Animals
8.1.6.1. Market Revenue and Forecast (2021-2033)
Chapter 9. Global Veterinary Assistive Reproduction Technology Market, By Product
9.1. Veterinary Assistive Reproduction Technology Market, by Product, 2024-2033
9.1.1. Normal Semen
9.1.1.1. Market Revenue and Forecast (2021-2033)
9.1.2. Sexed Semen
9.1.2.1. Market Revenue and Forecast (2021-2033)
Chapter 10. Global Veterinary Assistive Reproduction Technology Market, By Conception Method
10.1. Veterinary Assistive Reproduction Technology Market, by Conception Method, 2024-2033
10.1.1. Artificial Insemination
10.1.1.1. Market Revenue and Forecast (2021-2033)
10.1.2. Embryo Transfer (MOET)
10.1.2.1. Market Revenue and Forecast (2021-2033)
10.1.3. IVF
10.1.3.1. Market Revenue and Forecast (2021-2033)
Chapter 11. Global Veterinary Assistive Reproduction Technology Market, Regional Estimates and Trend Forecast
11.1. North America
11.1.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.1.2. Market Revenue and Forecast, by Product (2021-2033)
11.1.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.1.4. U.S.
11.1.4.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.1.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.1.4.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.1.5. Rest of North America
11.1.5.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.1.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.1.5.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.2. Europe
11.2.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.2.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.2.4. UK
11.2.4.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.2.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.4.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.2.5. Germany
11.2.5.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.2.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.5.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.2.6. France
11.2.6.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.2.6.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.6.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.2.7. Rest of Europe
11.2.7.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.2.7.2. Market Revenue and Forecast, by Product (2021-2033)
11.2.7.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.3. APAC
11.3.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.3.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.3.4. India
11.3.4.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.3.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.4.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.3.5. China
11.3.5.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.3.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.5.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.3.6. Japan
11.3.6.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.3.6.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.6.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.3.7. Rest of APAC
11.3.7.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.3.7.2. Market Revenue and Forecast, by Product (2021-2033)
11.3.7.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.4. MEA
11.4.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.4.4. GCC
11.4.4.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.4.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.4.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.4.5. North Africa
11.4.5.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.4.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.5.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.4.6. South Africa
11.4.6.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.4.6.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.6.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.4.7. Rest of MEA
11.4.7.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.4.7.2. Market Revenue and Forecast, by Product (2021-2033)
11.4.7.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.5. Latin America
11.5.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.5.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.5.4. Brazil
11.5.4.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.5.4.2. Market Revenue and Forecast, by Product (2021-2033)
11.5.4.3. Market Revenue and Forecast, by Conception Method (2021-2033)
11.5.5. Rest of LATAM
11.5.5.1. Market Revenue and Forecast, by Animal Type (2021-2033)
11.5.5.2. Market Revenue and Forecast, by Product (2021-2033)
11.5.5.3. Market Revenue and Forecast, by Conception Method (2021-2033)
Chapter 12. Company Profiles
12.1. Genus Plc
12.1.1. Company Overview
12.1.2. Product Offerings
12.1.3. Financial Performance
12.1.4. Recent Initiatives
12.2. URUS Group LP
12.2.1. Company Overview
12.2.2. Product Offerings
12.2.3. Financial Performance
12.2.4. Recent Initiatives
12.3. CRV
12.3.1. Company Overview
12.3.2. Product Offerings
12.3.3. Financial Performance
12.3.4. Recent Initiatives
12.4. SEMEX
12.4.1. Company Overview
12.4.2. Product Offerings
12.4.3. Financial Performance
12.4.4. Recent Initiatives
12.5. Select Sires, Inc.
12.5.1. Company Overview
12.5.2. Product Offerings
12.5.3. Financial Performance
12.5.4. Recent Initiatives
12.6. Swine Genetics International
12.6.1. Company Overview
12.6.2. Product Offerings
12.6.3. Financial Performance
12.6.4. Recent Initiatives
12.7. National Dairy Development Board
12.7.1. Company Overview
12.7.2. Product Offerings
12.7.3. Financial Performance
12.7.4. Recent Initiatives
12.8. STgenetics
12.8.1. Company Overview
12.8.2. Product Offerings
12.8.3. Financial Performance
12.8.4. Recent Initiatives
12.9. VikingGenetics
12.9.1. Company Overview
12.9.2. Product Offerings
12.9.3. Financial Performance
12.9.4. Recent Initiatives
12.10. Geno SA
12.10.1. Company Overview
12.10.2. Product Offerings
12.10.3. Financial Performance
12.10.4. Recent Initiatives
Chapter 13. Research Methodology
13.1. Primary Research
13.2. Secondary Research
13.3. Assumptions
Chapter 14. Appendix
14.1. About Us
14.2. Glossary of Terms
Cross-segment Market Size and Analysis for
Mentioned Segments
Additional Company Profiles (Upto 5 With No Cost)
Additional Countries (Apart From Mentioned Countries)
Country/Region-specific Report
Go To Market Strategy
Region Specific Market DynamicsRegion Level Market Share Import Export AnalysisProduction AnalysisOthers